# Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

> **NCT05665725** · PHASE1 · COMPLETED · sponsor: **Timothy Voorhees** · enrollment: 11 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Siltuximab

## Key facts

- **NCT ID:** NCT05665725
- **Lead sponsor:** Timothy Voorhees
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-31
- **Primary completion:** 2023-09-27
- **Final completion:** 2024-09-06
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05665725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05665725, "Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05665725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*